NO171345C - Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator - Google Patents

Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator

Info

Publication number
NO171345C
NO171345C NO862096A NO862096A NO171345C NO 171345 C NO171345 C NO 171345C NO 862096 A NO862096 A NO 862096A NO 862096 A NO862096 A NO 862096A NO 171345 C NO171345 C NO 171345C
Authority
NO
Norway
Prior art keywords
procedure
preparation
pharmaceutical preparations
plasminogen activator
tissue plasminogen
Prior art date
Application number
NO862096A
Other languages
English (en)
Other versions
NO862096L (no
NO171345B (no
Inventor
Michael Denis Johnston
Henry Berger
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO862096L publication Critical patent/NO862096L/no
Publication of NO171345B publication Critical patent/NO171345B/no
Publication of NO171345C publication Critical patent/NO171345C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
NO862096A 1985-05-28 1986-05-27 Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator NO171345C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (3)

Publication Number Publication Date
NO862096L NO862096L (no) 1986-12-01
NO171345B NO171345B (no) 1992-11-23
NO171345C true NO171345C (no) 1993-03-03

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862096A NO171345C (no) 1985-05-28 1986-05-27 Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator

Country Status (22)

Country Link
US (2) US4929444A (no)
JP (1) JPH0759517B2 (no)
AU (1) AU567236B2 (no)
BE (1) BE904830A (no)
CA (1) CA1300008C (no)
CH (1) CH665356A5 (no)
DE (1) DE3617752A1 (no)
DK (1) DK163173C (no)
ES (2) ES8800601A1 (no)
FI (1) FI85335C (no)
FR (1) FR2583984B1 (no)
GB (1) GB2176702B (no)
GR (1) GR861366B (no)
HU (1) HU195733B (no)
IL (1) IL78938A (no)
IT (1) IT1191926B (no)
LU (1) LU86444A1 (no)
NL (1) NL8601355A (no)
NO (1) NO171345C (no)
NZ (1) NZ216307A (no)
PT (1) PT82646B (no)
SE (1) SE462016B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR861365B (en) * 1985-05-28 1986-09-29 Wellcome Found Novel formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
NL8701113A (nl) * 1986-05-12 1987-12-01 Wellcome Found Nieuwe farmaceutische toepassing.
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
DK0643772T3 (da) * 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
WO1997023500A1 (en) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
DK0827751T3 (da) * 1996-09-06 2003-03-31 Chemo Sero Therapeut Res Inst Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid
WO2003022997A2 (en) * 2001-09-07 2003-03-20 Global Biotech Inc. Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US9045796B2 (en) * 2003-06-20 2015-06-02 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US8822535B2 (en) * 2005-04-20 2014-09-02 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (no) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
NL191755C (nl) * 1982-10-29 1996-07-02 Mitsui Toatsu Chemicals Plasminogeenactivator en trombolytisch middel.
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
GR861366B (en) 1986-09-29
CA1300008C (en) 1992-05-05
DK163173C (da) 1992-06-22
IT1191926B (it) 1988-03-31
HUT41638A (en) 1987-05-28
BE904830A (fr) 1986-11-27
FI85335B (fi) 1991-12-31
DK246786A (da) 1986-11-29
PT82646A (en) 1986-06-01
ES555353A0 (es) 1987-11-16
ES8800601A1 (es) 1987-11-16
DK246786D0 (da) 1986-05-27
IT8648065A0 (it) 1986-05-27
FI862227A (fi) 1986-11-29
FR2583984A1 (fr) 1987-01-02
SE8602405L (sv) 1986-11-29
US4929444A (en) 1990-05-29
US4968617A (en) 1990-11-06
AU567236B2 (en) 1987-11-12
JPH0759517B2 (ja) 1995-06-28
FR2583984B1 (fr) 1989-06-02
GB2176702B (en) 1989-07-05
FI862227A0 (fi) 1986-05-27
DE3617752A1 (de) 1986-12-04
PT82646B (pt) 1989-01-30
AU5796486A (en) 1986-12-04
ES557374A0 (es) 1988-06-01
ES8802439A1 (es) 1988-06-01
NO862096L (no) 1986-12-01
IL78938A0 (en) 1986-09-30
GB8612780D0 (en) 1986-07-02
NO171345B (no) 1992-11-23
HU195733B (en) 1988-07-28
FI85335C (fi) 1992-04-10
GB2176702A (en) 1987-01-07
NL8601355A (nl) 1986-12-16
NZ216307A (en) 1989-10-27
SE8602405D0 (sv) 1986-05-27
JPH06183995A (ja) 1994-07-05
CH665356A5 (de) 1988-05-13
IL78938A (en) 1993-02-21
SE462016B (sv) 1990-04-30
DK163173B (da) 1992-02-03
DE3617752C2 (no) 1988-06-30
LU86444A1 (fr) 1986-12-05

Similar Documents

Publication Publication Date Title
NO171344C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
NO171345C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
NO169493C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptid-derivater
NO864126D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridon-derivater.
NO170480C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenoksyeddiksyre-derivater
NO168770C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO854194L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende antracyklinglykosider.
NO864425L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklyl-oksoftalazinyl-eddiksyre-derivater
NO172343C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive askorbinsyrederivater
NO170629C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater
NO169014C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive distamycinderivater
NO167026C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO872551D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO170482C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karboksamid-derivater
ES550808A0 (es) Procedimiento de obtencion de preparados farmaceuticos de liberacion gradual prolongada
NO171592C (no) Fremgangsmaate for fremstilling av aktive cinnolin-derivater
NO168299C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater
NO862372D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO169069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-alkoksy-2-aminopropylaminderivater
NO874200L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO864101L (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilinderivater.
NO171108C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-desmetyl-mevalonsyrederivater
NO873423D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO872233D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO875359D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater